Nektar Therapeutics Stock Price

-0.37 (-1.95%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Nektar Therapeutics NKTR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.37 -1.95% 18.63 12:40:31
Open Price Low Price High Price Close Price Prev Close
18.94 18.52 19.42 19.00
Bid Price Ask Price Spread News
18.60 18.64 0.04 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,457 163,773 $ 18.77 $ 3,073,437 1,115,301 15.395 - 26.75
Last Trade Time Type Quantity Stock Price Currency
12:40:47 1 $ 18.601 USD

Nektar Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.34B 179.40M 89.64M $ 114.62M $ - -2.52 -6.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Nektar Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NKTR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.5520.0018.1419.01981,7420.080.43%
1 Month21.5322.6218.1419.72821,534-2.90-13.47%
3 Months17.1026.7516.8821.401,277,6071.538.95%
6 Months17.1626.7515.39519.511,149,1451.478.57%
1 Year19.2626.7515.39520.081,087,778-0.63-3.27%
3 Years92.5592.5513.6334.182,007,807-73.92-79.87%
5 Years15.72111.3611.4136.281,878,7692.9118.51%

Nektar Therapeutics Description

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Your Recent History
Nektar The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.